An ad-free and cookie-free website.
Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Sage Therapeutics Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.
We show how SAGE stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Pharmaceutical Preparation Manufacturing industry.
Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing new pathways with the goal of improving brain health, and its depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Its mission is to make medicines that matter so people can get better, sooner.
Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)
Stocks with higher market capitalization often have lower risk. (↑↓)
Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)
Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)
A newly-updated free resource. Connect and refer a friend today.